FDA Approves AKEEGA for BRCA2-Mutated Prostate Cancer Treatment
Listen to Original Audio
0:00 / 0:00
Full Transcript
The U.S. FDA has approved AKEEGA as the first precision therapy for treating BRCA2-mutated metastatic castration-sensitive prostate cancer. This breakthrough therapy has shown a 54% reduction in disease progression compared to standard care.
The approval marks a significant advancement in precision medicine for patients with BRCA2 mutations, potentially improving treatment outcomes for a challenging cancer type, according to Buffalo News.